BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 23246116)

  • 1. An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy.
    Cheng Y; Liu Y; Xu D; Zhang D; Yang Y; Miao Y; He S; Xu Q; Li E
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167122. PubMed ID: 38492783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.
    Schrama D; Voigt H; Eggert AO; Xiang R; Zhou H; Schumacher TN; Andersen MH; thor Straten P; Reisfeld RA; Becker JC
    Cancer Immunol Immunother; 2008 Jan; 57(1):85-95. PubMed ID: 17605009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four genetic polymorphisms of lymphotoxin-alpha gene and cancer risk: a systematic review and meta-analysis.
    Huang Y; Yu X; Wang L; Zhou S; Sun J; Feng N; Nie S; Wu J; Gao F; Fei B; Wang J; Lin Z; Li X; Xu L; Gao X; Ye M; Duan S
    PLoS One; 2013; 8(12):e82519. PubMed ID: 24349304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system.
    Yoshioka Y; Watanabe H; Morishige T; Yao X; Ikemizu S; Nagao C; Ahmad S; Mizuguchi K; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
    Biomaterials; 2010 Mar; 31(7):1935-43. PubMed ID: 19853911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
    Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphotoxin α induces apoptosis, necroptosis and inflammatory signals with the same potency as tumour necrosis factor.
    Etemadi N; Holien JK; Chau D; Dewson G; Murphy JM; Alexander WS; Parker MW; Silke J; Nachbur U
    FEBS J; 2013 Nov; 280(21):5283-97. PubMed ID: 23815148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation.
    Narimatsu S; Yoshioka Y; Watanabe H; Masano T; Morishige T; Yao X; Tanabe A; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
    Cytokine; 2011 Nov; 56(2):489-93. PubMed ID: 21871814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
    Shibata H; Abe Y; Yoshioka Y; Nomura T; Sato M; Kayamuro H; Kawara T; Arita S; Furuya T; Nagano K; Yoshikawa T; Kamada H; Tsunoda S; Tsutsumi Y
    Cytokine; 2010 Apr; 50(1):75-83. PubMed ID: 20045350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy.
    Morishige T; Yoshioka Y; Narimatsu S; Ikemizu S; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
    Cytokine; 2013 Feb; 61(2):578-84. PubMed ID: 23246116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biology and signal transduction pathways of the Lymphotoxin-αβ/LTβR system.
    Remouchamps C; Boutaffala L; Ganeff C; Dejardin E
    Cytokine Growth Factor Rev; 2011; 22(5-6):301-10. PubMed ID: 22152226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphotoxin-alpha and cardiovascular disease: clinical association and pathogenic mechanisms.
    Naoum JJ; Chai H; Lin PH; Lumsden AB; Yao Q; Chen C
    Med Sci Monit; 2006 Jul; 12(7):RA121-4. PubMed ID: 16810143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of New Biologics through Creation of a Functional Cytokine Mutant].
    Kamada H
    Yakugaku Zasshi; 2015; 135(7):843-9. PubMed ID: 26135083
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.